"Referring Physician Template Letter This letter is"
Referring Physician Template Letter: This letter is intended to introduce referring physicians (Internal Medicine, Family Practice, Gynecologists) to the National CT Colonography Trial and encourage their support for participant enrollment. Dear [Referring Physician] I am writing to introduce you to the National CT Colonography Trial and to ask you for assistance with enrolling patients from your practice. Endorsed by the American Cancer Society (ACS), the trial will open at [name of institution] in early January 2005. Study participants must be at least 50 years old, scheduled for a screening colonoscopy, and not had a colonoscopy in the past five years. Colorectal cancer is the third most common cancer and second leading cause of malignant death in the United States. Doctor Stephen F. Sener, MD, President of the American Cancer Society confirms: “As physicians, we know some of our patients are reluctant to get screened for colorectal cancer. The National CT Colonography Trial will evaluate the effectiveness of this non-invasive screening technology, and thus may help remove a barrier to getting more people 50 and older screened. If more people get screened, more lives will be saved.” CT colonography (CTC) represents a promising new colorectal cancer screening approach that is now both technically and clinically feasible. Although preliminary performance data suggests that CTC will be highly competitive with other structural screening tests, an unbiased assessment of its sensitivity and specificity in a screening population requires a prospective, blinded comparison with the “gold standard” of colonoscopy. The primary aim of the National CT Colonography Trial is to clinically validate the widespread use of CTC in a screening population for the detection of colorectal neoplasia. Each study participant will have a CTC followed by a colonoscopy on the same day. The study will address important clinical applications of CTC through several components: comparison of the clinical performance of the CTC, in a blinded fashion, to colonoscopy, optimization of the CTC technique to incorporate new technological advances, and evaluation of patient preferences and their corresponding cost-effectiveness implications. I have enclosed study brochures to share with patients who you recommend schedule a screening colonoscopy. Study information presented by a patients’ primary care physician will greatly aid participant recruitment. Please refer patients who would like more information to [name of contact] whose contact information is on the brochure. The trial is funded by the National Cancer Institute and coordinated by the American College of Radiology Imaging Network (ACRIN). The full protocol can be viewed at: www.acrin.org (ACRIN 6664). Should you have any questions, please contact me at [contact information]. Thank you for your time and interest. I appreciate your support of this important trial. Sincerely yours,